SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Stage IV Prostate Cancer AJCC v8 Clinical Trial

Official title:

Randomized Phase III Trial of SBRT Versus Hypofractionated Radiotherapy for Salvage of Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma After Radical Prostatectomy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06205316
• Other study ID #: GMROA2255
• Secondary ID: NCI-2023-1089722
• Status: Recruiting
• Phase: Phase 3
• Start date: January 22, 2024
• Est. completion date: January 22, 2030

Study information

• Verified date: January 2024
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with prostate adenocarcinoma that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to a limited number of sites (oligometastatic). SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumors cells and have fewer side effects. SBRT may work just as well as hypofractionated radiation therapy at treating patients with biochemically recurrent or oligometastatic prostate cancer, but with a shorter treatment time and possibly fewer side effects.

Description:

PRIMARY OBJECTIVE:

I. To determine if salvage SBRT is non-inferior to moderately hypofractionated radiation therapy regarding treatment related rates of genitourinary (GU) and gastrointestinal (GI) grade 3 or higher within 2-years.

EXPLORATORY OBJECTIVES:

I. After completion of radiation therapy, determine the incidence of:

Ia. Disease free survival (DFS), defined as the first occurrence of new clinical failure (local recurrence, regional recurrence, or distant metastasis) after salvage radiation therapy (RT); Ib. Grade 2 or greater GU and GI toxicity at 3 years (Common Terminology Criteria for Adverse Events [CTCAE] version 4); Ic. Grade 3 or greater GU and GI toxicity at 3 years (CTCAE version 4); Id. Quality of life following completion of radiation therapy; Ie. Impotence after the use of radiation therapy at 3 years; If. Freedom from biochemical failure (FFBF) at 5 years; Ig. Local failure at 5 years; Ih. Regional failure at 5 years; Ii. Distant failure at 5 years; Ij. Salvage androgen deprivation therapy (ADT) use (SAD) at 5 years; Ik. Progression free survival: using clinical, biochemical and SAD as events at 5 years; Il. Overall survival at 5 years; Im. Disease-specific survival at 5 years. II. Determine the impact of salvage SBRT and hypofractionated radiation therapy (HFRT) on quality of life.

III. Determine prostate and normal structure movement during RT with the use of scans.

IV. Correlate pathologic and radiologic findings with outcomes. V. Correlate pre-RT prostate specific antigen (PSA) levels with outcomes. VI. Prospectively collect information that will help to define dose-volume relationships of normal structures with acute and chronic toxicity.

VII. Allow for future research of pathologic risk factors that may influence prognosis; this information will help us to attempt to characterize their presence in prostate cancer with high-risk features after prostatectomy and their potential effect on outcomes.

VIII. Prospectively record contours that were manually drawn versus (vs.) edited from artificial intelligence (AI)-generated contours.

IX. Determine the impact of using artificial intelligence (AI) tools for automatic segmenting prostate bed and other organs at risk, in terms of toxicities and outcome.

X. Determine if there are any significant differences in dose-volumes results for cases that involved AI-autosegmentation vs. cases without.

XI. Determine the relationship between the use of AI-autosegmentation tools with toxicities and outcome.

XII. Different online daily imaging guidance systems are allowed in this trial, including x-rays, conventional Feldkamp-Davis-Kress (FDK)-based cone beam computed tomography (CBCT), and iterative CBCT. Subgroup analysis will be performed to determine patient alignment accuracy and toxicities rates with respect to different online daily imaging systems.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients undergo SBRT over 15-20 minutes every other day for a total of 5 treatments over 1-2 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive androgen deprivation therapy for up to 18 months, as clinically indicated. Patients undergo bone scan and positron emission tomography (PET) at screening and treatment failure, and undergo magnetic resonance imaging (MRI) and blood sample collection throughout the study.

GROUP II: Patients undergo hypofractionated radiation therapy over 15-20 minutes once per day for a total of 20 treatments over 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients may receive androgen deprivation therapy for up to 18 months, as clinically indicated. Patients undergo bone scan and PET at screening and treatment failure, and undergo MRI and blood sample collection throughout the study.

After completion of study treatment, patients follow up at 3 months, 12 months, annually until year 5 and then every other year until death.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 118
• Est. completion date: January 22, 2030
• Est. primary completion date: January 22, 2030
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed prostate adenocarcinoma at the time of surgery

• Pathologic stages T2-T3b, Nx or N0-1, M0-1 as staged by the pathology report (American Joint Committee on Cancer [AJCC] Criteria 8th edition [Ed.])

• PSA post radical prostatectomy = 0.1 and < 2.0 ng/mL = 90 days prior to enrollment, obtained = 6 weeks after surgery

• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 assessed = 90 days of enrollment

• Patients must sign institutional review board (IRB) approved study specific informed consent

• Patients must complete all required pre-entry tests within the specified time frames

• Patients must be able to start treatment (ADT or radiation) = 120 days of study registration

• Patients must be = 18 years old

• Prostate cancer up to oligometastatic disease, up to 5 sites

Exclusion Criteria:

• Previous pelvic radiation

• Prior androgen deprivation therapy for prostate cancer and PSA = 0.1 ng/mL

• Active rectal diverticulitis, Crohn's disease affecting the rectum, or ulcerative colitis (non-active diverticulitis and Crohn's disease not affecting the rectum are allowed)

• Prior systemic chemotherapy for prostate cancer

• History of proximal urethral stricture requiring dilatation

• Major medical, addictive, or psychiatric illness which in the investigator's opinion, will prevent the consent process, completion of the treatment and/or interfere with follow-up. (Consent by legal authorized representative is not permitted for this study)

• History of myocardial infarction or decompensated congestive heart failure (CHF) within the last 6 months

• On a transplant list

• More than oligometastatic disease > 5 metastatic sites

Related Conditions & MeSH terms

• Adenocarcinoma
• Biochemically Recurrent Prostate Carcinoma
• Carcinoma
• Oligometastatic Prostate Carcinoma
• Prostatic Neoplasms
• Recurrence
• Stage IIB Prostate Cancer AJCC v8
• Stage IIC Prostate Cancer AJCC v8
• Stage III Prostate Cancer AJCC v8
• Stage IV Prostate Cancer AJCC v8

Intervention

Drug:
• Antiandrogen Therapy
Receive ADT

Procedure:
• Biospecimen Collection
Undergo blood sample collection
• Bone Scan
Undergo bone scan

Radiation:
• Hypofractionated Radiation Therapy
Undergo hypofractionated radiation therapy

Procedure:
• Magnetic Resonance Imaging
Undergo MRI
• Positron Emission Tomography
Undergo PET scan

Radiation:
• Stereotactic Body Radiation Therapy
Undergo SBRT

Other:
• Survey Administration
Ancillary study

Locations

Country	Name	City	State
United States	Mayo Clinic in Arizona	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of grade 3 or higher genitourinary (GU)/gastrointestinal (GI) radiation treatment-related adverse events	Defined as the proportion of patients experiencing an increase in GU/GI Common Terminology Criteria for Adverse Events version 5.0 to grade 3+ compared to pre-radiation therapy GU/GI toxicity over the number of patients eligible for toxicity evaluation at 2 years from the start of radiation therapy. This endpoint will be compared between patients treated with stereotactic body radiation therapy and hypofractionated radiation therapy.	Up to 2 years

External Links

•   Mayo Clinic Clinical Trials